Hepatitis B core protein modulators

A compound represented by:

• wherein
• Y is S(O)y, wherein y is 2;
• Rz is H;
• Rm′ and Rm are each H;
• R21 is selected for each occurrence from the group consisting of H, and C1-6alkyl;
• q is 0, 1, or 2;
• R22 is selected from the group consisting of hydroxyl, nitro, cyano, carboxy, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, NR′R″, —C(O)—C1-6alkyl, —C(O)—C1-6alkoxy, —C(O)—NR′R″, —C(═NH)—NR′R″, X2-phenyl (optionally substituted by one, two or three substituents represented by R63), phenyl (optionally substituted by one, two or three substituents represented by R63), 5-6 membered monocyclic heteroaryl (optionally substituted by one, two or three substituents represented by R63), 9-10 membered bicyclic heteroaryl (optionally substituted by one, two or three substituents represented by R73), C3-6cycloalkyl, —S(O)w-C1-6alkyl (where w is 0, 1 or 2), —S(O)w—NR′R″ (where w is 0, 1 or 2), and —NR′—S(O)w, (where w is 0, 1 or 2);
• R′ is selected, independently for each occurrence, from H, methyl, ethyl, and propyl;
• R″ is selected, independently for each occurrence, from H, methyl, ethyl, propyl, butyl, —C(O)-methyl and —C(O)-ethyl, or R′ and R″ taken together with the nitrogen to which they are attached may form a 4-7 membered heterocycle;
• each of moieties R4, R5, R6, R7, R8, R9, and R10 is independently selected for each occurrence from the group consisting of hydrogen, C1-6alkyl, C2-6alkynyl, C2-6alkenyl, halogen, hydroxyl, nitro, cyano, and NR′R″;
• R63 is selected independently at each occurrence from the group consisting of H, halogen, hydroxyl, nitro, cyano, carboxy, C1-6alkyl, —C(O)—O—C1-6alkyl, heterocycle (optionally substituted by halogen or NR′R′), —C(O)—NR′R″, —C(═NH)—NR′R″, heteroaryl, phenyl, benzyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, carboxy, NR′R″, —C(O)—C1-6alkyl, —C(O)—C1-6alkoxy, C3-6cycloalkyl, —S(O)w—C1-6alkyl (where w is 0, 1 or 2), —S(O)w—NR′R″ (where w is 0, 1 or 2), —NR′—S(O)w—C1-6alkyl (where w is 0, 1 or 2), X2—R69;
• R69 is selected from the group consisting of H, halogen, hydroxyl, nitro, cyano, C1-6alkyl, —C(O)—O—C1-6alkyl, heterocycle (optionally substituted by halogen or NR′R′),), —C(O)—NR′R″, —C(═NH)—NR′R″, heteroaryl, phenyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, carboxy, NR′R″, —C(O)—C1-6alkyl, —C(O)—C1-6alkoxy, C3-6cycloalkyl, —S(O)w—C1-6alkyl (where w is 0, 1 or 2), —S(O)w—NR′R″ (where w is 0, 1 or 2), and —NR′—S(O)w— C1-6alkyl (where w is 0, 1 or 2),
• X2 is selected from S(O)w (wherein w is 0, 1, or 2), O, CH2, or NR′;
• wherein for each occurrence, C1-6alkyl may be optionally substituted with one, two, three or more substituents selected from the group consisting of halogen, hydroxyl, nitro, cyano, carboxy, C2-6alkenyl, C2-6alkynyl, NR′R″, —NR′—S(O)w—C1-6alkyl (where w is 0, 1 or 2), and S(O)w—NR′R″(where w is 0, 1 or 2);
• C1-6alkoxy may be optionally substituted with one, two, three or more substituents selected from the group consisting of halogen, hydroxyl, nitro, cyano, carboxy, C1-6alkyl, NR′R″, —NR′—S(O)w— C1-6alkyl (where w is 0,1 or 2), and S(0)w—NR′R″ (where w is 0, 1 or 2);
• and pharmaceutically acceptable salts thereof.